（Fund9’s Portfolio）

Taudia provides ultra-sensitive and scalable protein biomarker detection from blood samples.
By combining innovative dual-conjugated antibody probes with a fully automated, sample-to-answer system, they enable precise, hands-free quantitation of protein biomarkers in blood and other complex matrices—all in under four hours.
Taudia first addresses the critical missing link in Alzheimer’s disease research and diagnosis. Looking ahead, their technology will also accelerate drug development for Parkinson’s disease and other neurological disorders.